Tablet
Sponsors
Alumis Inc., Spero Therapeutics Inc., UZ Leuven, Imbria Pharmaceuticals Inc., Crinetics Pharmaceuticals Inc.
Conditions
AnxietyArthroplasty ComplicationsChronic Inducible Urticaria and Chronic Spontaneous UrticariaClassic Congenital Adrenal HyperplasiaClassic congenital adrenal hyperplasiaCognitive DisorderFearHealthy
Phase 2
Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder
Active, not recruitingIRCT201506203930N38
Start: 2016-05-28Target: 40Updated: 2018-02-22
[M20-186] A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
Active, not recruitingJPRN-jRCT2031210119
Start: 2021-04-27Target: 260Updated: 2025-07-18
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus
Active, not recruitingCTIS2022-502105-15-00
Start: 2023-10-20Target: 136Updated: 2025-11-14
A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
RecruitingCTIS2024-520031-33-00
Start: 2025-09-16Target: 57Updated: 2025-09-05
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
RecruitingCTIS2024-515125-28-00
Start: 2025-12-08Target: 130Updated: 2025-12-05
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension
Not yet recruitingCTIS2024-519578-38-00
Target: 61Updated: 2026-01-07
Phase 3
A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
CompletedCTIS2023-503785-22-00
Start: 2024-03-25End: 2025-05-28Target: 1454Updated: 2025-06-09
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Not yet recruitingCTIS2024-519579-24-00
Target: 54Updated: 2026-01-23
Phase 4
Large Doses of Methylprednisolone Combined With Gabapentin in Total Knee Arthroplasty
CompletedNCT04653415
Start: 2019-06-01End: 2020-05-01Updated: 2020-12-04
Perioperative oral analgesia versus intravenous analgesia for knee arthroscopy, a randomized, double-blinded, non-inferiority trial. OVIKA-trial - S68618
Active, not recruitingCTIS2024-510789-17-00
Start: 2024-09-03Target: 108Updated: 2024-06-03
Unknown Phase
Wayfinding Intervention in High-Fidelity Long-Term Memory
CompletedNCT04253587
Start: 2019-10-01End: 2021-12-15Updated: 2023-02-27
Use of Exhaled Particles to Assess Lung Pharmacokinetics
CompletedNCT04914273
Start: 2021-06-14End: 2021-08-03Updated: 2024-10-15
The Effect of Two Distraction Methods on the Level of Pain, Fear and Anxiety in Children
CompletedNCT05588687
Start: 2022-02-01End: 2022-06-01Updated: 2023-04-11
Virtual Reality Program to Reduce Stress in Neonatal Nurses
CompletedNCT06192368
Start: 2024-06-19End: 2025-03-05Updated: 2025-08-24
Virtual Reality Training for Inhibitory Control in Neurocognitive Disorders
RecruitingNCT06597591
Start: 2024-11-18End: 2027-11-18Target: 48Updated: 2024-11-20